Drugs Made In America Acquisition Ii Corp. (DMII) Stock Price & Analysis
Drugs Made In America Acquisition Ii Corp. (DMII) rose 0.00% to USD 10.1 as of July 26, 2026 at 14:08 UTC, according to Nexqual real-time market data.
DMII last closed at USD 10.1; the session ranged USD 10.1–10.1 on volume of 217 shares. Market capitalization is —, with a 52-week range of USD 9.86–10.11 (NGM). Source: Nexqual, July 26, 2026 at 14:08 UTC.
Key Statistics (as of July 26, 2026 at 14:08 UTC)
| Price | USD 10.1 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 10.1 |
| Open | USD 10.1 |
| Day Range | USD 10.1 – 10.1 |
| 52-Week Range | USD 9.86 – 10.11 |
| Volume | 217 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (DMII)
Nexqual's technical model rates DMII "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 26, 2026 at 14:08 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.35 (neutral) |
| vs SMA50 | Above (USD 10.08) |
| MACD | 0 (positive) |
From Drugs Made In America Acquisition Ii Corp.'s Latest SEC 10-K Filing (filed 2026-04-15)
Key Strengths & Strategy (as disclosed to the SEC)
- The aim will be for this business to have end-to-end capability from plant-based raw material production for a spectrum of controlled substances (the Active Pharmaceutical Ingredients ("API")) to drug manufacturing and prescriptions filled by pharmacies or directly to the patients.   The post-business combination company would aim to grow revenues building on an addressable market for the estimated $44 billion plant-based production segment, API market, and generic medications.
- Because we are able to complete our initial business combination using our cash, debt or equity securities, or a combination of the foregoing, we have the flexibility to use the most efficient combination that will allow us to tailor the consideration to be paid to the target business to fit its needs and desires.
Partnerships
- If any third party refuses to execute an agreement waiving such claims to the monies held in the trust account, our management will perform an analysis of the alternatives available to it and will enter into an agreement with a third party that has not executed a waiver only if management believes that such third party's engagement would be significantly more beneficial to us than any alternative.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CEPV | Cantor Equity Partners V, Inc. | USD 10.44 | ▲ 0.19% |
| CEPF | Cantor Equity Partners IV, Inc. | USD 10.5 | ▲ 0.42% |
| EVAC | EQV Ventures Acquisition Corp. | USD 10.23 | ▲ 0.2% |
| KFII | K&F Growth Acquisition Corp. II | USD 10.59 | ▲ 0% |
| CRAQ | Cal Redwood Acquisition Corp. | USD 10.35 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 14:08 UTC. This page is informational and not investment advice.